Tvardi Therapeutics, Inc. Cash Flow Statement
TVRD|11 years of annual SEC 10-K data (FY2014-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 11 fiscal years. All figures from audited SEC 10-K filings.
Tvardi Therapeutics, Inc. used $79M in operating cash flow and negative free cash flow of $79M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -6.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$85.5M | -$88.4M | $8.4M | -$106.4M | -$74.0M | -$58.1M | -$57.3M | -$24.7M | -$17.7M | -$4.0M | -$6.3M |
| Depreciation & Amortization | $248.0K | $248.0K | $209.0K | $198.0K | $370.0K | $495.0K | $1.5M | $839.0K | $783.0K | $789.0K | $1.0M |
| Operating Cash Flow | -$78.7M | -$60.1M | -$5.5M | -$109.2M | -$22.3M | -$54.8M | -$47.4M | -$21.5M | -$17.6M | $2.8M | -$6.0M |
| Capital Expenditures | $43.0K | $39.0K | $349.0K | $18.0K | $73.0K | $58.0K | $717.0K | $20.0K | $42.0K | $5.0K | $5.0K |
| Free Cash Flow | -$78.8M | -$60.1M | -$5.8M | -$109.2M | -$22.4M | -$54.9M | -$48.1M | -$21.5M | -$17.7M | $2.8M | -$6.0M |
| FCF Margin | -188.2% | -261.1% | -4.3% | -549.4% | -166.1% | -6024.7% | -55927.9% | -565.3% | -556.6% | 23.6% | -507.2% |